系统性红斑狼疮

1.  Uramoto KM, Mitchet CJ Jr, Thumboo J, et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum. 1999 Jan;42(1):46-50.

• 全文
• 摘要

2.  Siegel M, Lee SL. The epidemiology of systemic lupus erythematosus. Semin Arthritis Rheum. 1973;3(1):1-54.

• 摘要

3.  Mitchet CJ Jr, McKenna CH, Elveback LR, et al. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1985 Feb;60(2):105-13.

• 摘要

4.  Nived O, Sturfelt G, Wollheim F. Systemic lupus erythematosus in an adult population in southern Sweden: incidence, prevalence and validity of ARA revised classification criteria. Br J Rheumatol. 1985 May;24(2):147-54.

• 摘要

5.  Johnson AE, Gordon C, Palmer RG, et al. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum. 1995 Apr;38(4):551-8.

• 摘要

6.  Nai-Zheng Z. Epidemiology of systemic lupus erythematosus (SLE) in China. Proceedings of the 2nd International Conference on SLE, Tokyo: Professional Postgraduate Services, Int. 1989:29-31.

7.  Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308-18.

• 摘要

8.  Masi AT, Kaslow RA. Sex effects in SLE: a clue to pathogenesis. Arthritis Rheum. 1978 May;21(4):480-4.

• 摘要

9.  Lawrence JS, Martins CL, Drake GL. A family survey of lupus erythematosus. 1. Heritability. J Rheumatol. 1987 Oct;14(5):913-21.

• 摘要

10.  Deapen D, Escalante A, Weinrib L, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 1992 Mar;35(3):311-8.

• 摘要

11.  Taylor PR, Carugati A, Fadok VA, et al. Heirarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med. 2000 Aug 7;192(3):359-66.

• 全文
• 摘要

12.  Reveille JD. The molecular genetics of systemic lupus erythematosus and Sjögren's syndrome. Curr Opin Rheumatol. 1992 Oct;4(5):644-56.

• 摘要

13.  Demirci FY, Manzi S, Ramsey-Goldman R, et al. Association of a common interferon regulatory factor 5 (IRF5) variant with increased risk of systemic lupus erythematosus (SLE). Ann Hum Genet. 2007 May;71(Pt 3):308-11.

• 全文
• 摘要

14.  Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am. 1994 Feb;20(1):61-86.

• 摘要

15.  Blomgren SE, Condemi JJ, Vaughan JH. Procainamide-induced lupus erythematosus: clinical and laboratory observations. Am J Med. 1972 Mar;52(3):338-48.

• 摘要

16.  Sclienger RG, Bircher AJ, Meier CR. Minocycline-induced lupus: a systematic review. Dermatology. 2000;200(3):223-31.

• 摘要

17.  Gordon MM, Porter D. Minocycline induced lupus: case series in the West of Scotland. J Rheumatol. 2001 May;28(5):1004-6.

• 摘要

18.  McKellar G, Porter D, Burden D. Terbinafine as a cause of cutaneous lupus erythematosus. Rheumatology (Oxford). 2004 Feb;43(2):249.

• 摘要

19.  Gunnarsson I, Nordmark B, Hassan Bakri A et al. Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA. Rheumatology (Oxford). 2000 Aug;39(8):886-93.

• 全文
• 摘要

20.  Siddiqui MA, Khan IA. Isoniazid-induced lupus erythematosus presenting with cardiac tamponade. Am J Ther. 2002 Mar-Apr;9(2):163-5.

• 摘要

21.  Scheinfeld N. Impact of phenytoin therapy on the skin and skin disease. Expert Opin Drug Saf. 2004 Nov;3(6):655-65.

• 摘要

22.  Pelizza L, De Luca P, La Pesa M, et al. Drug-induced systemic lupus erythematosus after 7 years of treatment with carbamazepine. Acta Biomed. 2006 Apr;77(1):17-9.

• 摘要

23.  James JA, Kaufman KM, Farris AD, et al. An increased prevalence of Ebstein Barr virus infection in young patients suggests a possible aetiology for SLE. J Clin Invest. 1997 Dec 15;100(12):3019-26.

• 全文
• 摘要

24.  Chan OT, Madio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev. 1999 Jun;169:107-21.

• 摘要

25.  Shevack EM. Regulatory T cells in autoimmunity. Annu Rev Immunol. 2000;18:423-49.

• 摘要

26.  Munoz L, van Bavel C, Franz S, et al. Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus. 2008 May;17(5):371-5.

• 摘要

27.  Grimaldi CM. Sex and systemic lupus erythematosus: the role of the sex hormones estrogen and prolactin on the regulation of autoreactive B cells. Curr Opin Rheumatol. 2006 Sep;18(5):456-61.

• 摘要

28.  Jungers P, Dougados M, Pelissier C, et al. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum. 1982 Jun;25(6):618-23.

• 摘要

29.  Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005 Jun 21;142(12 Pt 1):953-62.

• 摘要

30.  Kaslow RA, Masi AT. Age, sex, and race effects on mortality from systemic lupus erythematosus in the United States. Arthritis Rheum. 1978 May;21(4):473-9.

• 摘要

31.  Ginzler EM, Diamond HS, Weiner M, et al. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum. 1982 Jun;25(6):601-11.

• 摘要

32.  Boodhoo KD, Liu S, Zuo X. Impact of sex disparities on the clinical manifestations in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Medicine (Baltimore). 2016 Jul;95(29):e4272.

• 全文
• 摘要

33.  Font J, Pallares L, Cervera R, et al. Systemic lupus erythematosus in the elderly: clinical and immunological characteristics. Ann Rheum Dis. 1991 Oct;50(10):702-5.

• 全文
• 摘要

34.  Molokhia M, Hoggart C, Patrick AL, et al. Relation of risk of SLE to west African admixture in a Caribbean population. Hum Genet. 2003 Mar;112(3):310-8.

• 摘要

35.  Deabndt M, Vittecoq O, Descamps V, et al. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol. 2003 Feb;22(1):56-61.

• 摘要

36.  Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol. 2005 Apr;24(2):178-81.

• 摘要

37.  D'Cruz DP, Khamashta MA, Hughes GRV. Systemic lupus erythematosus. Lancet. 2007 Feb 17;369(9561):587-96.

• 摘要

38.  Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998 May;41(5):778-99.

• 摘要

39.  Jiang F, Li S, Jia C. Smoking and the risk of systemic lupus erythematosus: an updated systematic review and cumulative meta-analysis. Clin Rheumatol. 2015 Nov;34(11):1885-92.

• 摘要

40.  Harel-Meir M. Sherer Y, Shoenfeld Y. Tobacco smoking and autoimmune disease. Nat Clin Pract Rheumatol. 2007 Dec;3(12):707-15.

• 摘要

41.  Montes RA, Mocarzel LO, Lanzieri PG, et al. Smoking and its association with morbidity in systemic lupus erythematosus evaluated by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index: preliminary data and systematic review. Arthritis Rheumatol. 2016 Feb;68(2):441-8.

• 全文
• 摘要

42.  Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008 Feb;67(2):195-205.

• 全文
• 摘要

43.  Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep;40(9):1725.

• 摘要

44.  Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677-86.

• 全文
• 摘要

45.  McKinley PS, Ouellette SC, Winkel GH. The contributions of disease activity, sleep patterns and depression to fatigue in SLE: a proposed model. Arthritis Rheum. 1995 Jun;38(6):826-34.

• 摘要

46.  Zandman-Goddard G, Schoenfeld Y. SLE and infections. Clin Rev Allergy Immunol. 2003 Aug;25(1):29-40.

• 摘要

47.  Bernatsky S. Boivin JF. Joseph L, et al. Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum. 2005 Oct 15;53(5):781-4.

• 全文
• 摘要

48.  Estes D, Christian CL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore). 1971 Mar;50(2):85-95.

• 摘要

49.  Vitali C, Doria A, Tincani A. International survey on the management of patients with SLE. I. General data on the participating centers and the results of a questionnaire regarding mucocutaneous involvement. Clin Exp Rheumatol. 1996 Nov-Dec;14(suppl 16):S17-22.

• 摘要

50.  Dubois EL, Tuffanelli DL. Clinical manifestations of SLE: computer analysis of 520 cases. JAMA. 1964 Oct 12;190:104-11.

• 摘要

51.  Feinglass EJ, Arnett FC, Dorsch CA, et al. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore). 1976 Jul;55(4):323-39.

• 摘要

52.  Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with SLE: comparison with the Framingham study. Am J Epidemiol. 1997 Mar 1;145(5):408-15.

• 全文
• 摘要

53.  Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999 Feb;42(2):338-46.

• 全文
• 摘要

54.  Memet B, Ginzler EM. Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med. 2007 Aug;28(4):441-50.

• 摘要

55.  Duron L, Cohen-Aubart F, Diot E, et al. Shrinking lung syndrome associated with systemic lupus erythematosus: a multicenter collaborative study of 15 new cases and a review of the 155 cases in the literature focusing on treatment response and long-term outcomes. Autoimmun Rev. 2016 Oct;15(10):994-1000.

• 摘要

56.  Beyan E, Beyan C, Turan M. Hematological presentation in systemic lupus erythematosus and its relationship with disease activity. Hematology. 2007 Jun;12(3):257-61.

• 摘要

57.  Hallegua DS, Wallace DJ. Gastrointestinal manifestations of systemic lupus erythematosus. Curr Opin Rheumatol. 2000 Sep;12(5):379-85.

• 摘要

58.  Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997 Sep;40(9):1601-11.

• 摘要

59.  Smeenk R, Brinkman K, van den Brink H, et al. Antibodies to DNA in patients with systemic lupus erythematosus: their role in the diagnosis, the follow-up and the pathogenesis of the disease. Clin Rheumatol. 1990 Mar;9(1 suppl 1):100-10.

• 摘要

60.  Eaton RB, Schnneider G, Schur PH. Enzyme immunoassay for antibodies to native DNA. Specificity and quality of antibodies. Arthritis Rheum. 1983 Jan;26(1):52-62.

• 摘要

61.  Weening JJ, D'Agati V, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004 Feb;15(2):241-50.

• 全文
• 摘要

62.  Hochberg MC, Boyd RE, Ahearn JM, et al. Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine (Baltimore). 1985 Sep;64(5):285-95.

• 摘要

63.  Schneebaum AN, Singleton JD, West SG, et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med. 1991 Jan;90(1):54-62.

• 摘要

64.  Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002 Apr;46(4):1019-27.

• 摘要

65.  von Mühlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum. 1995 Apr;24(5):323-58.

• 摘要

66.  Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the anti-phospholipid syndrome. Blood. 2007 Jan 15;109(2):422-30.

• 全文
• 摘要

67.  Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271-7.

• 摘要

68.  Rodríguez Huerta MD, Trujillo-Martín MM, Rúa-Figueroa Í, et al. Healthy lifestyle habits for patients with systemic lupus erythematosus: a systemic review. Semin Arthritis Rheum. 2016 Feb;45(4):463-70.

• 摘要

69.  Bruce IN, Mak VC, Hallett DC, et al. Factors associated with fatigue in patients with systemic lupus erythematosus. Ann Rheum Dis. 1999 Jun;58(6):379-81.

• 全文
• 摘要

70.  Zonana-Nacach A, Roseman JM, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups, VI: factors associated with fatigue within five year of criteria diagnosis. Lupus. 2000;9(2):101-9.

• 摘要

71.  William HJ, Egger MJ, Singer JZ, et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol. 1994 Aug;21(8):1457-62.

• 摘要

72.  Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991 Jan 17;324(3):150-4.

• 全文
• 摘要

73.  Carneiro JR, Sato EI. Double-blind, randomised, placebo controlled trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999 Jun;26(6):1275-9.

• 摘要

74.  Herzinger T, Plewig G, Röcken M. Use of sunscreens to protect against ultra-violet induced lupus erythematosus. Arthritis Rheum. 2004 Sep;50(9):3045-6.

• 全文
• 摘要

75.  Henderson LK, Masson P, Craig JC, et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2013 Jan;61(1):74-87.

• 摘要

76.  Tunnicliffe DJ, Palmer SC, Henderson L, et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev. 2018 Jun 29;(6):CD002922.

• 全文
• 摘要

77.  Mok CC, Ying KY, Yim CW, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis. 2016 Jan;75(1):30-6.

• 摘要

78.  Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015 Jan 6;162(1):18-26.

• 摘要

79.  Tian SY, Feldman BM, Beyene J, et al. Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis. J Rheumatol. 2014 Oct;41(10):1998-2007.

• 摘要

80.  Zhang X, Ji L, Yang L, et al. The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis. Int Urol Nephrol. 2016 May;48(5):731-43.

• 摘要

81.  Lee YH, Song GG. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials. Lupus. 2015 Dec;24(14):1520-8.

• 摘要

82.  Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64:797-808.

• 全文
• 摘要

83.  Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012 Nov;71(11):1771-82.

• 全文
• 摘要

84.  Kasitanon N, Fine DM, Haas M, et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus. 2006;15(6):366-70.

• 摘要

85.  Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppresion in lupus nephritis: results from the MAINTAIN Nephritis trial. Ann Rheum Dis. 2010 Dec;69(12):2083-9.

• 全文
• 摘要

86.  Maneiro JR, Lopez-Canoa N, Salgado E, et al. Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis. Rheumatology (Oxford). 2014 May;53(5):834-8.

• 摘要

87.  Tian SY, Feldman BM, Beyene J, et al. Immunosuppressive therapies for the maintenance treatment of proliferative lupus nephritis: a systematic review and network metaanalysis. J Rheumatol. 2015 Aug;42(8):1392-400.

• 摘要

88.  Tamirou F, D'Cruz D, Sangle S, et al; MAINTAIN Nephritis Trial Group. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. 2016 Mar;75(3):526-31.

• 全文
• 摘要

89.  Rodríguez SC, Olguín AM, Miralles CP, et al. Characteristics of meningitis caused by ibuprofen: report of 2 cases with recurrent episodes and review of the literature. Medicine (Baltimore). 2006 Jul;85(4):214-20.

• 摘要

90.  Antman EM, Bennet JS, Daugherty A, et al. Use of non-steroidal antiinflammatory drugs, an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007 Mar 27;115(12):1634-42.

• 全文
• 摘要

91.  Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001 Dec 20;345(25):1809-17.

• 全文
• 摘要

92.  Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos. 2001 Apr;29(4 Pt 2):601-5.

• 全文
• 摘要

93.  Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15;61(9):1168-78.

• 全文
• 摘要

94.  Van Vollenhoven R, Zamani O, Wallace DJ, et al. Belimumab, a BLyS-specific inhibitor, reduces disease activity and severe flares in seropositive SLE patients: BLISS-76 study. Ann Rheum Dis. 2010;69(suppl 3):74.

• 全文

95.  Petri M, Levy RA, Merrill JT, et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares, and prednisone use in patients with seropositive SLE: combined efficacy results from the phase 3 BLISS-52 and -76 studies. Arthritis Rheum. 2010;62(suppl 10):190.

96.  Manzi S, Sánchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012 Nov;71(11):1833-8.

• 全文
• 摘要

97.  Sciascia S, Radin M, Yazdany J, et al. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review. Autoimmun Rev. 2017 Mar;16(3):287-93.

• 全文
• 摘要

98.  Merrill JT, Ginzler EM, Wallace DJ, et al. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Oct;64(10):3364-73.

• 全文
• 摘要

99.  Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Feb 26;377(9767):721-31.

• 摘要

100.  Boyce EG, Fusco BE. Belimumab: review of use in systemic lupus erythematosus. Clin Ther. 2012 May;34(5):1006-22.

• 摘要

101.  Wei LQ, Liang YG, Zhao Y, et al. Efficacy and safety of belimumab plus standard therapy in patients with systemic lupus erythematosus: a meta-analysis. Clin Ther. 2016 May;38(5):1134-40.

• 摘要

102.  Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther. 2006;8(3):R83.

• 全文
• 摘要

103.  Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002 Oct;46(10):2673-7.

• 全文
• 摘要

104.  Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003 Feb;48(2):455-9.

• 全文
• 摘要

105.  Rovin BH, Furie R, Latinis K, et al; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012 Apr;64(4):1215-26.

• 全文
• 摘要

106.  Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus. 2011 Jun;20(7):709-16.

• 摘要

107.  Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan;62(1):222-33.

• 全文
• 摘要

108.  Weidenbusch M, Römmele C, Schröttle A, et al. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 2013 Jan;28(1):106-11.

• 全文
• 摘要

109.  Furie RA, Leon G, Thomas M, et al; PEARL-SC Study. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015 Sep;74(9):1667-75.

• 摘要

110.  Kalunian KC, Merrill JT, Maciuca R, et al. A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016 Jan;75(1):196-202.

111.  Khamashta M, Merrill JT, Werth VP, et al; CD1067 study investigators. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Nov;75(11):1909-16.

• 全文
• 摘要

112.  Merrill JT, Wallace DJ, Petri M, et al; Lupus Interferon Skin Activity (LISA) Study Investigators. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov;70(11):1905-13.

• 摘要

113.  Department of Health. Clinical guidelines for immunoglobulin use (2nd edition). May 2008 [internet publication].

• 全文

114.  Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5 year period. A multicentre prospective study of 1000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1999 May;78(3):167-75.

• 摘要

115.  Cervera R, Abarca-Costalago M, Abramovicz D, et al. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". AAutoimmun Rev. 2006 Mar;5(3):180-6.

• 摘要

116.  Lee YH, Choi SJ, Ji JD, et al. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016 Jun;25(7):727-34.

• 摘要

117.  Fors Nieves CE, Izmirly PM. Mortality in systemic lupus erythematosus: an updated review. Curr Rheumatol Rep. 2016 Apr;18(4):21.

• 摘要

118.  Qian J, Wang Y, Huang C, et al. Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: a PRISMA-compliant systematic review and meta-analysis. Autoimmun Rev. 2016 Mar;15(3):250-7.

• 摘要

119.  Ballocca F, D'Ascenzo F, Moretti C, et al. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiol. 2015 Nov;22(11):1435-41.

• 全文
• 摘要

120.  Bernatsky S, Joseph L, Boivin JF, et al. The relationship between cancer and medication exposures in systemic lupus erythematosus: a case-cohort study. Ann Rheum Dis. 2008 Jan;67(1):74-9.

• 摘要

121.  Schneider V, Levesque LE, Zhang B, et al. Association of selective and conventional non-steroidal anti inflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol. 2006 Nov 1;164(9):881-9.

• 全文
• 摘要

122.  Breuer GS, Baer A, Dahan D, Nesher G. Lupus-associated pancreatitis. Autoimmun Rev. 2006 May;5(5):314-8.

• 摘要

123.  Nesher G, Breuer GS, Temprano K, et al. Lupus-associated pancreatitis. Semin Arthritis Rheum. 2006 Feb;35(4):260-7.

• 摘要

124.  Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995 Apr 13;332(15):993-7.

• 全文
• 摘要

125.  Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus. 2004;13(9):673-8.

• 摘要

126.  Manger K, Wildt L, Kalden JR, et al. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev. 2006 Apr;5(4):269-72.

127.  Soares PM, Borba EF, Bonfa E, et al. Gonad evaluation in male systemic lupus erythematosus. Arthritis Rheum. 2007 Jul;56(7):2352-61.

• 全文
• 摘要

128.  Oshiro BT, Silver RM, Scott JR, et al. Antiphospholipid antibodies and fetal death. Obstet Gynecol. 1996 Apr;87(4):489-93.

• 摘要

129.  Out HJ, Bruinse HW, Christiaens GC, et al. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol. 1992 Jul;167(1):26-32.

• 摘要

130.  Kutteh WH, Lyda EC, Abraham SM, et al. Association of anticardiolipin antibodies and pregnancy loss in women with systemic lupus erythematosus. Fertil Steril. 1993 Sep;60(3):449-55.

• 摘要

131.  Kozora E, Ellison MC, West S. Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery. Arthritis Rheum. 2006 Aug 15;55(4):628-35.

• 全文
• 摘要

132.  Wang X, Yan S, Liu C, et al. Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Osteoporos Int. 2016 Apr;27(4):1413-23.

• 摘要

133.  Henegar CE, Eudy AM, Kharat V, et al. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. Lupus. 2016 May;25(6):617-26.

• 摘要

134.  Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptive in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24):2550-8.

• 全文
• 摘要

135.  Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24):2539-49.

• 全文
• 摘要

136.  Clowse ME, Magder L, Whitter F, et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006 Nov;54(11):3640-7.

• 全文
• 摘要

137.  Battafarano DF, Battafarano NJ, Larsen L et al. Antigen specific antibody responses in lupus patients following immunization. Arthritis Rheum. 1998 Oct;41(10):1828-34.

• 摘要

138.  Holvast A, Huckriede A, Wilschut J, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis. 2006 Jul;65(7):913-8.

• 全文
• 摘要

139.  Huang Y, Wang H, Wan L, et al. Is systemic lupus erythematosus associated with a declined immunogenicity and poor safety of influenza vaccination? A systematic review and meta-analysis. Medicine (Baltimore). 2016 May;95(19):e3637.

• 全文
• 摘要

140.  Pugès M, Biscay P, Barnetche T, et al. Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis. Rheumatology (Oxford). 2016 Sep;55(9):1664-72.

• 全文
• 摘要

141.  Senecal JL, Bertrand C, Coutlee F. Severe exacerbation of systemic lupus erythematosus after hepatitis B vaccination and importance of pneumococcal vaccination in patients with autosplenectomy. Arthritis Rheum. 1999 Jun;42(6):1307-8.

• 全文
• 摘要